

REMARKS

The first paragraph of the specification has been amended to correct the claim to priority of related applications and to identify the U.S. Serial number of a co-filed, related application.

Claims 2, 16-26, 29, 40-45, 47, 61-72, 84, and 86-88 are pending. Claims 1, 3-15, 27, 28, 30-39, 46, 48-60, 73-83, 85, and 89 have been cancelled without prejudice or disclaimer. Claims 2, 16-26, 29, 40-45, 47, 61-72, 84, and 86-88 have been amended to recite the apical sodium co-dependent bile acid transport inhibitor shown as entry A-1 in Table 1 on page 7. The claims have also been amended to recite the synonyms of ZD-4522 and NK-104, namely rosuvastatin and pitavastatin, respectively. Claim 44 has been amended to correct a typographical error in the daily dose range.

No new matter has been added.

Prompt and favorable examination on the merits of the pending claims is respectfully solicited.

Respectfully submitted,

Date: July 3, 2003

By:



Ajay Pathak  
Registration No. 38,266

BANNER & WITCOFF, LTD.  
1001 G Street, NW  
Washington, DC 20001  
202-824-3000